concentrato per soluzione per infusione. clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator’s Choice (IC) Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)
This study is for women with advanced ovarian (or related) cancer that has come back and isn't responding to platinum-based chemotherapy. Researchers are comparing a new treatment called Luveltamab Tazevibulin with standard chemotherapy to see if it works better and is safe.
For: Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)Austria · Finland · Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
This study is testing if adding two new drugs, nivolumab and ipilimumab, to standard chemotherapy works better than chemotherapy alone for advanced lung cancer. It seeks to understand if this new combination helps people live longer.
For: Stage IV Non-Small Cell Lung Cancer (NSCLC)Spain · Ireland · Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
This study looks at new ways to treat early-stage lung cancer. It compares standard chemotherapy with treatments that combine chemotherapy with new medicines called nivolumab and ipilimumab, to see if they work better at stopping the cancer from returning.
For: Early Stage Non-Small Cell Lung Cancer (NSCLC)France · Italy · Romania